CN112912501A - 寡核苷酸分子及其在肿瘤治疗中的应用 - Google Patents

寡核苷酸分子及其在肿瘤治疗中的应用 Download PDF

Info

Publication number
CN112912501A
CN112912501A CN201980067436.3A CN201980067436A CN112912501A CN 112912501 A CN112912501 A CN 112912501A CN 201980067436 A CN201980067436 A CN 201980067436A CN 112912501 A CN112912501 A CN 112912501A
Authority
CN
China
Prior art keywords
nucleic acid
acid molecule
lhpp
cell
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067436.3A
Other languages
English (en)
Inventor
康涛
李龙承
姜武林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Original Assignee
Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd filed Critical Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Publication of CN112912501A publication Critical patent/CN112912501A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01001—Inorganic diphosphatase (3.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供了用于治疗肿瘤的寡聚核酸，其可以为小激活核酸分子，所述小激活核酸分子可以是靶向LHPP基因启动子区的双链或单链RNA分子，包含第一核酸链和第二核酸链。还提供了包含所述小激活核酸分子和可选的药学上可接受的载体的药物组合物及其应用。使用所述小激活核酸分子以及使用所述药物组合物可以上调LHPP基因在细胞中的表达及治疗与LHPP基因表达不足或减少相关的疾病或状况。

Description

PCT国内申请，说明书已公开。

Claims (52)

  1. PCT国内申请，权利要求书已公开。
CN201980067436.3A 2019-01-30 2019-06-25 寡核苷酸分子及其在肿瘤治疗中的应用 Pending CN112912501A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910092375 2019-01-30
CN2019100923758 2019-01-30
PCT/CN2019/092720 WO2020155534A1 (zh) 2019-01-30 2019-06-25 寡核苷酸分子及其在肿瘤治疗中的应用

Publications (1)

Publication Number Publication Date
CN112912501A true CN112912501A (zh) 2021-06-04

Family

ID=71841762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067436.3A Pending CN112912501A (zh) 2019-01-30 2019-06-25 寡核苷酸分子及其在肿瘤治疗中的应用

Country Status (6)

Country Link
US (1) US20220096516A1 (zh)
EP (1) EP3919618A4 (zh)
JP (2) JP2022529562A (zh)
KR (1) KR20210121079A (zh)
CN (1) CN112912501A (zh)
WO (1) WO2020155534A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104630219A (zh) * 2013-11-15 2015-05-20 上海交通大学医学院附属瑞金医院 抑癌基因IRX1的saRNA分子及其组合物和其应用
CN106480028A (zh) * 2016-10-12 2017-03-08 上海市第七人民医院 TPO基因的saRNA分子及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604532C (en) * 2005-04-15 2017-03-07 The Regents Of The University Of California Small activating rna molecules and methods of use
US9045752B2 (en) * 2010-03-11 2015-06-02 The Regents Of The University Of California NKX3-1 saRNA and KLF4 saRNA and uses thereof
US9045751B2 (en) * 2010-04-28 2015-06-02 The Regents Of The University Of California Modified small activating RNA molecules and methods of use
DK3071696T3 (da) * 2013-11-22 2019-10-07 Mina Therapeutics Ltd C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse
WO2016170348A2 (en) * 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104630219A (zh) * 2013-11-15 2015-05-20 上海交通大学医学院附属瑞金医院 抑癌基因IRX1的saRNA分子及其组合物和其应用
CN106480028A (zh) * 2016-10-12 2017-03-08 上海市第七人民医院 TPO基因的saRNA分子及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SRAVANTH K. HINDUPUR1 等: "The protein histidine phosphatase LHPP is a tumour suppressor", NATURE, vol. 555, no. 7698, pages 678 - 682, XP055837822, DOI: 10.1038/nature26140 *
XING MENG等: "Small activating RNA binds to the genomic target sitein a seed-region-dependent manner", NUCLEIC ACIDS RESEARCH, vol. 44, no. 5, pages 2274 - 2282 *

Also Published As

Publication number Publication date
JP2024028895A (ja) 2024-03-05
EP3919618A1 (en) 2021-12-08
US20220096516A1 (en) 2022-03-31
KR20210121079A (ko) 2021-10-07
WO2020155534A1 (zh) 2020-08-06
EP3919618A4 (en) 2023-11-08
JP2022529562A (ja) 2022-06-23

Similar Documents

Publication Publication Date Title
JP6414886B2 (ja) 抗癌治療に用いられる長鎖非コードｒｎａ
CN107267625B (zh) lncRNA作为生物标志物在肝癌诊疗中的用途
KR20140074997A (ko) 신경병성 질환에서 마이크로rna
WO2019196887A1 (zh) 一种新型小激活rna
AU2015249265A1 (en) Multiple targeted RNAi for the treatment of cancers
KR20150004414A (ko) Kras-관련 질환을 치료하기 위한 유기 조성물
CA3075784A1 (en) Methods for treating triple-negative breast cancer comprising a cdk19 inhibitory agent
CN112996913B (zh) 寡聚核酸分子及其应用
He et al. A Circular RNAs: Emerging roles and new insights in human cancers
WO2019196883A1 (zh) 一种激活p21基因表达的方法
CA2932910A1 (en) Methods for diagnosing and treating metastatic cancer
CN113260702B (zh) 寡聚核酸分子及其在急性间歇性卟啉症治疗中的应用
WO2011038700A1 (zh) Fam3b基因的抑制剂和抑制剂组合物及抑制方法以及抑制剂在制药中的应用
KR102324924B1 (ko) 항암제 선별방법
CN112912501A (zh) 寡核苷酸分子及其在肿瘤治疗中的应用
Zhang et al. Downregulation of MiR-1538 promotes proliferation and metastasis of colorectal cancer by targeting DNMT3A
US20120190729A1 (en) Mirna inhibition of six1 expression
JP2022541212A (ja) 治療的使用のための、ヒト遺伝子ＪＡＫ１又はＪＡＫ３の発現を標的とするＳｉＲＮＡ配列
CN111808954B (zh) lncRNA及其在疾病中的应用
CN111518905B (zh) lncRNA在肺腺癌诊疗中的用途
CN113774137B (zh) 检测生物标志物表达的试剂在制备鉴定白血病耐药和/或不良预后的试剂盒中的应用
CN114085832B (zh) 用于抑制PRR14基因的siRNA分子
WO2021249064A1 (zh) 靶向mitf基因的核酸分子及其用途
WO2021209608A1 (en) Medical methods and medical uses
CN117460826A (zh) 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination